In clinical trials Enzalutamide (Xtandi) significantly increased the overall survival and radiographic progression-free survival of men when compared with placebo. The trial, called PREVAIL evaluated men who were asymptomatic and minimally symptomatic, chemotherapy-naive with metastatic castration-resistant prostate cancer.

The researchers expanded the data analysis and evaluated the effect of Xtandi on the men’s health-related quality of life (HRQoL), including pain, and skeletal-related events.

When they went back to the trial data they found that the median treatment duration of the men was 16.6 months in the Xtandi group and 4.6 months in the placebo group. Their analyses showed significant treatment differences in change from baseline to week 61 with men taking the Xtandi compared with placebo. Median time to deterioration was 11.3 months in the Xtandi group against 5.6 months in the placebo groups.

A significantly greater proportion of men in the Xtandi group than in